Back to company

Perfusion Tech ApS: Financial statements 2018

CVR: 38238213

Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -261,728 and a net result of DKK -238,245 compared with DKK -271,716 the year before. Equity amounted to DKK -452,673.

Gross Profit
-261,728 kr.
Profit/Loss
-238,245 kr.
Equity
-452,673 kr.
Total Assets
470,718 kr.

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2018--262 t.-238 t.-453 t.-
2017--278 t.-272 t.-214 t.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Perfusion Tech ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2018

Perfusion Tech ApS: The 2017 annual report is outMay 23, 2018

Perfusion Tech ApS has published its annual report for 2017. Gross profit came to DKK -278,036, and the net result was DKK -271,716.

About Perfusion Tech ApS

Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity amounted to DKK -9,640,655.